Among a variety of immunodeficient mouse strains the nonobese diabetic (NOD)/LtSz scid/scid strain appears to be most useful in allowing the engraftment of human AML. However, the large variability in ability to engraft and the levels of engraftment reached have not been explained. To address these issues we have investigated the NOD/SCID repopulating ability of 27 newly diagnosed AML samples. Patients were selected for the absence of internal tandem duplications in the Flt3 gene as we previously reported this mutation to be associated with an enhanced engraftment potential in this model. We observed that secondary AML (n = 6) had a significantly increased level of engraftment when compared to primary AML (n = 21, median levels 73.3% for secondary AML vs 8.94% for primary AML, P = 0.01). Within the primary AML, a significantly higher engraftment was observed in the FAB class M0 than in FAB classes M2, M4 and M5. Within primary AML, samples of patients who failed to respond to the initial therapy gave rise to a higher level of engraftment than samples of patients who did respond to therapy. A similar observation of an increased engraftment correlating with a poorer patient prognosis could be made when applying cytogenetic risk stratification. However, within the primary AML the most important clinical parameter correlating with the level of engraftment appeared to be the patient's WBC count at diagnosis (P = 0.0000). Covariate analysis with the WBC count as a covariate could also fully explain the differences observed in the cytogenetic risk groups, or on the basis of the initial therapy response. Although large differences could be observed, the ability to engraft the NOD/SCID mice was not linked to either the autonomous or cytokine-induced proliferation in vitro. As the leukemic cobblestone area-forming cell frequencies also revealed no correlation with repopulation in the NOD/SCID model, we consider it very likely that the level of engraftment reflects the in vivo proliferative ability of the AML samples assayed rather than the number of leukemia-initiating cells infused into the NOD/SCID mice. Phenotypic analysis based on the expression of CD33, CD34 and CD38 before and after passage in NOD/SCID showed that in 10 out of 16 samples investigated phenotypes were different. In summary, in addition to the Flt3 internal tandem duplications we have identified a series of clinical parameters that determine the NOD/SCID repopulating ability of AML samples, whilst our data strongly suggest that AML in NOD/SCID does not reflect the leukemic process in the patient. Leukemia (2000) 14, 889-897.
Introduction
The term acute myeloid leukemia (AML) encompasses a range of clonal hematopoietic disorders with an aberrant proliferation and differentiation. Generally, these leukemic cells are committed to the myelo-monocytic lineage although they might also show erythroid or megakaryocytic lineage charac- teristics. Analysis of clonal markers [1] [2] [3] has shown that leukemic transformation may occur at the level of the pluripotent or the less primitive, committed, hematopoietic stem/ progenitor cell. We and others have recently shown that these primitive leukemic progenitors can give rise to long-term malignant hemopoiesis in vitro when supported by a feeder of murine stromal cells. [4] [5] [6] In normal hemopoiesis murine transplantation models have played a crucial role in our understanding of the most primitive stem/progenitor cells able to give multilineage engraftment. Until recently, research in normal human hemopoiesis was hampered by a lack of suitable in vivo assays. This has changed with the availability of chimeric models in which human hemopoietic progenitors exhibit multilineage engraftment when injected into sublethally irradiated immunodeficient mice. [7] [8] [9] Immunodeficient mice can also support the growth of malignant progenitors of chronic myeloid leukemia (CML) and AML. [10] [11] [12] [13] Among a variety of immunodeficient mouse strains, we and others have evaluated, the nonobese diabetic (NOD)/LtSz scid/scid strain appears to be most useful in allowing the engraftment of human AML progenitors. 14, 15 In contrast to the CB17/SCID strain, which is only defective in B and T cell function, this strain is characterized by an additional functional deficit in NK cell function as well as defective antigen-presenting cells and an absence of circulating complement. Injection of AML cells into these mice reportedly results in engraftment and development of leukemia in the murine hematopoietic tissue in a similar way to that seen in patients. 16 Although in most AML cases the cells able to initiate engraftment (SCID leukemia-initiating cells or SL-IC) were phenotypically characterized as CD34 + CD38 − , 6 some cases have been reported in which these SL-IC were CD34 − CD38 − . 4 The ability of SL-IC to engraft after a prior in vitro incubation with 5-FU suggests that these cells, analogous to normal hemopoiesis, belong to a more quiescent population. 5 The large variability between AML samples in their ability to engraft the bone marrow of NOD/SCID mice has thus far not been explained. Also, little is known about the correlation between engraftment in NOD/SCID and clinical or biological characteristics of the AML sample.
To address several of these issues we have investigated a series of newly diagnosed AML samples in their ability to engraft in NOD/SCID mice. These data were correlated with clinical parameters such as prognosis, cytogenetics, white blood cell counts and FAB classification. We also looked for correlations with the leukemic cobblestone area-forming cell (L-CAFC) content of the samples as well as the short-term in vitro proliferation in response to a panel of cytokines. As we have previously shown that AML samples from patients with an internal tandem duplication in the Flt3 gene (Flt3/ITD) represent a distinct subpopulation of AML with a greatly enhanced potential to engraft in the NOD/SCID 27 these samples were excluded from this study.
Materials and methods

Patient samples
Diagnosis of bone marrow samples of patients with newly diagnosed AML were obtained after informed consent. Cases were classified according to the French-American-British committee (FAB). 17 Mononuclear cells were isolated by Ficoll separation followed by T cell depletion, typically resulting in a population containing over 95% blasts. After isolation, cells were subjected to controlled freezing and stored in liquid nitrogen. Before use cells were thawed by stepwise dilution in Iscove's modified Dulbecco's medium (IMDM; Gibco, Breda, The Netherlands) containing 1% BSA. After thawing viability varied between 70 and 90% as assessed by dye exclusion.
After diagnosis patients were treated according to studies of the adult Dutch-Belgian Hemato-Oncology Group HOVON and the Dutch childhood leukemia group SNWLK. Patients were treated according to protocols HOVON-29 (less than 60 years of age, 11 patients), 18 HOVON-4 (less than 60 years, three patients), 19 HOVON-31 (60 years +, four patients), AML-11 (60 years+, five patients) 20 or SNWLK-ANLL-94 protocols (less than 15 years of age, two patients). Two patients received palliative treatment only. In these protocols induction therapy included an anthracycline and cytarabine and in patients less then 60 years allogeneic and autologous stem cell transplantation or intensive chemotherapy for consolidation were applied as post-remission therapy.
Stratification according to karyotype risk groups
As cytogenetic aberrations are thought to be one of the most important prognostic factors for AML 21, 22 patients were stratified into three groups, ie a good risk group consisting of patients defined by a karyotype of t(8;21), t(15;17) or inv (16) and a poor risk group defined by del(5), del(7), or deletions of the q-arms of these chromosomes, t (6, 9) , alterations in the 11q23 region or the presence of multiple aberrations (more than three) in the karyotype. All other karyotypic aberrations and the normal karyotype were included in an intermediate risk group.
Determination of the short-term proliferative response to single cytokine stimulation
To determine the proliferative response to single cytokine stimulation we used a thymidine incorporation assay. As monocytes and macrophages are known to produce many cytokines and thus potentially may perturb the results we removed these cells prior to their use in culture by adherence to plastic (1 h incubation at 37°C in alpha-MEM (Gibco) + 1% BSA (Sigma, St Louis, MO, USA). The non-adherent cells were plated in 96-well plates at a density of 2 × 10 4 cells/well in serum-free medium 23 and cultured for 6 days. The cytokines used were either hIL-3 (25 ng/ml; a gift from Genetics Institute, Cambridge, MA, USA), hGM-CSF (10 ng/ml; Immunex, Seattle, WA, USA), hG-CSF (100 ng/ml; a gift from Amgen, Thousand Oaks, CA, USA), hM-CSF (100 U/ml, generously supplied by Genetics Institute) or hSCF (100 ng/ml, a gift from Amgen). After 6 days cells were incubated overnight with 0.1 Ci tritiated-thymidine (Amersham, Buckinghamshire, UK) per well and harvested on to nitro-cellulose filters. Thymidine incorporation was determined in a liquid scintillation counter (Pharmacia-LKB, Bromma, Sweden) as counts per minute (c.p.m.). All cultures were done in triplicate.
The stimulation index was calculated by dividing the mean c.p.m. of the triplicate cultures by the mean c.p.m. of a 30 Gy irradiated control of the sample.
Leukemic cobblestone area-forming cell assay
The cobblestone area-forming cell assay was performed as described. 24 Briefly, confluent FBMD-1 stromal layers in 96-well plates (Costar, Cambridge, MA, USA) were overlaid with AML cells in a limiting dilution set-up. The cells were cultured in medium consisting of IMDM (Gibco) supplemented with 10% heat-inactivated fetal calf serum (Summit Biotechnology, Fort Collins, CO, USA), 5% horse serum (Gibco), ␤-mercaptoethanol (5 × 10 −5 mol/l) and hydrocortisone-21-hemisuccinate (10 −6 mol/l, Sigma). rhIl-3 (8 ng/ml) and rhG-CSF (20 ng/ml) (both a generous gift of the Genetics Institute) were added to the medium and all cultures were performed at 37°C and 10% CO 2 in a humidified atmosphere.
Input values were equivalent to 1 × 10 5 nucleated cells/well and 12 dilutions three-fold apart were used for each sample with 15 replicates per dilution. The percentage of wells with at least one phase-dark clone (cobblestone area, consisting of at least five cells) beneath the stromal layer was determined weekly and leukemic CAFC (L-CAFC) frequencies were calculated using Poisson statistics. 25 Based on evidence from murine correlation studies it is assumed that both normal and leukemic cobblestone areas that are observed late in culture are indicators of primitive long-term repopulating cells in vivo, whilst early appearing clones are indicators of transiently repopulating and less primitive cells.
The NOD/SCID mouse model
NOD/SCID mice were bred in the Erasmus animal facility and housed under specified pathogen-free conditions, using laminar airflow units. Mice were supplied with sterilised food and acidified tap water to which 100 mg/I ciprofloxacine (Bayer AG, Leverkusen, Germany) was added. Both food and drink were available ad libitum.
Before transplantation of the AML cells the mice received a total body irradiation of 3.5 Gy gamma radiation ( 137 Cs source, Gammacell; Atomic Energy of Canada, Ottawa, Canada). Transplantation of the AML cells was done by injecting 3 × 10 7 AML cells in the lateral tail vein. After 30 days, the mice were sacrificed by CO 2 inhalation in accordance with the institutional animal research regulations.
Cell suspensions were made from both femora and used for flow cytometry.
Flow cytometry
To determine the percentage of AML cells in bone marrow suspensions from mice that had been transplanted, cells were stained with antibodies against the human common leukocyte antigen (CD45), CD34, CD33 and CD38 (CD45-FITC, CD38-FITC, CD33-PE and CD34-APC, all obtained from Coulter Immunotech, Marseille, France) and measured using a FACScalibur (Becton Dickinson Immunocytometry systems, San Jose, CA, USA). Analysis was done using the Cell Quest software package (Becton Dickinson). Erythrocytes were excluded from analysis by gating on forward and perpendicular light scatter whilst dead cells were excluded by staining with 7-amino-actinomycin D (7-AAD; Molecular Probes, Eugene, OR, USA).
Statistical analysis
Statistical analysis of the data was performed using the SPSS software package (SPSS, Chicago, IL, USA). Significance of differences for the proliferation, L-CAFC and SCID assays was determined by either the non-parametrical Mann-Whitney U test or the Kruskal-Wallis test for multiple independent parameters. Correlation analysis was performed using Spearman's rho test for nonparametrical correlation.
Results
Variability in the outgrowth of AML cells in the NOD/SCID mouse
The NOD/SCID mouse model was used to investigate the in vivo leukemia-initiating capacity of newly diagnosed AML. Due to the large number of cells needed for a reproducible engraftment (3 × 10 7 cells/mouse) and the limited availability of animals we were only able to analyze a limited number of samples (n = 27). Groups of three mice/sample were injected with AML cells and analyzed at day 30 after transplantation. We were unable to analyze samples of FAB class M3 as all samples of this type injected into NOD/SCID resulted in death of the mice within 24 h after injection (with the highest mortality within 1 h). This was most probably due to in vivo lysis of the cells resulting in intravascular coagulation.
Patient details of the analyzable samples are given in Table  1 . Analysis of the percentage of engraftment shows a clear variability between the FAB classes ( Figure 1 ). The M0 and M1 samples gave rise to the highest median level of chimerism whereas FAB M2 and M5 showed a low level of engraftment. As indicated by the large interquartile range there was an extreme variation within the M4 class. The median within this group was in the lower part of this range as most samples only induced a relatively low engraftment. A closer study of the clinical data indicated that the higher engraftment data in the FAB M4 class were by AML samples from patients that were likely to have had a previous history of MDS. Because we could not exclude the possibility that such so-called 'secondary AML' patient samples were also included in the other FAB class groups, we re-analyzed the other groups as well ( Figure  2 ). Indeed we found that in all cases the secondary AML samples induced a significantly higher level of NOD/SCID engraftment as compared to primary AML samples.
When we excluded the secondary AML samples from our anlyses, the highest level of engraftment was still observed in FAB class M0 and M1, however, statistical analysis showed only significant differences between classes M0 and M2, M4 or M5 (P = 0.036, 0.025 or 0.024, respectively). As we only had six secondary AML samples in our data set we were not Leukemia able to analyze the engraftment ability of population on the basis of FAB class.
A median engraftment of 8.9% was observed after pooling all primary AML samples irrespective of FAB class (Figure 3 ). In contrast, secondary AMLs showed a median engraftment of 73.3%, which was significantly different from that of primary AML samples (P = 0.01). Based on this clearly different ability of both populations to engraft in the NOD/SCID mouse the primary and secondary AML groups were separately analyzed in this study.
We also investigated whether the ability to engraft the NOD/SCID mouse could be correlated to the initial response of the patient towards therapy (Figure 4 ). In the primary AML samples there was a clear, although not significant, enhanced engraftment in the population who failed to achieve a complete remission (CR). Within the secondary AML samples no difference could be observed in engraftment between patients who achieved a CR and those who failed. Due to the low number of secondary AML samples in the group who failed to respond to therapy no significant differences between primary and secondary AML samples could be found. In the group of patients who achieved a CR the differences between these subtypes of AML were significant (P = 0.049). Further subdivision of the patients achieving a CR into patients who remained in CR and patients who relapsed within 23 months (our median observation period) showed no differences for both primary and secondary AML (data not shown).
The observation that, at least for the primary leukemias, there was a relationship between poor prognosis (ie therapy failure) and an increased ability to engraft the mice led us to investigate whether this observation could be related to other important clinical parameters associated with patient prognosis. Correlation analysis for the patient's age and the ability to engraft NOD/SCID revealed no relationship (data not shown). Application of cytogenetic risk stratification to the data indicated an increasing ability for the primary AML samples to engraft with a decreasing prognosis for the patient ( Figure 5 ). Although this relation was shown not to be significant, the most extreme responses were clearly in the poor prognosis group. As most secondary AML samples fell within the intermediate risk stratum no objective comparisons could be made within the other strata. In the intermediate risk group we could again observe a much higher level of engraftment for the secondary leukemias as compared to the primary leukemias (P = 0.026).
Because an increasing white blood cell count (WBC) at diagnosis is also associated with poor prognosis, we performed a correlation analysis for this parameter with regard to NOD/SCID repopulation ability. Even without taking into account the presence of both primary and secondary AML this was shown to be a highly significant parameter (P = 0.0001, data not shown). However, this correlation was only linked to the primary AML samples (P = 0.0000 compared to P = 0.4680 for secondary AML). As can be seen in Figure 6 , low WBC levels correlate with a low level of engraftment of primary AML samples in NOD/SCID. The observation that some samples fell outside of the 95% confidence interval suggest, however, that WBC counts are not the sole factor governing the NOD/SCID repopulating ability of primary AML.
Differences in surface marker expression after passage in the NOD/SCID mouse
To investigate whether expression of the surface markers CD34 and CD38 either before or after passage in NOD/SCID A total of 27 samples of patients with newly diagnosed AML were included in this study. Patients were selected to give a good representation throughout the FAB classes. Cytogenetics were determined for all samples and cytogenetic abnormalities are included if observed. Samples from AML-M3 patients are absent as we were unable to generate reliable results in the NOD/SCID using these samples. Initial therapy response was defined as 'CR' if the patient achieved a complete remission, 'No Cr' if the patient failed to achieve remission or only achieved a partial remission. 
Figure 3
Differences in the overall level of chimerism between primary and secondary AML. For legends see Figure 1 .
Figure 4
Relation between the level of engraftment in NOD/SCID and the initial therapy response of the patient. CR group: patients who achieved a complete remission in response to initial treatment; No CR group: patients who failed to respond to therapy or only achieved a partial remission; dark shaded bars: primary AML; light shaded bars: secondary AML. For further legends see Figure 1 .
could be linked to the engraftment of the mice, we performed a two-color flow cytometrical analysis. From the input phenotypes no correlations could be derived between the expression of CD34 and/or CD38 with regard to NOD/SCID repopulating ability. After passage in NOD/SCID only the CD34 − CD38 + phenotype in the primary AML samples showed a low although significant negative correlation with NOD/SCID repopulation (Pearson's correlation: −0.659, P = 0.014, data not shown). Correlation analysis between the phenotype of the samples before and after passage in NOD/SCID revealed no correlation (data not shown). As this suggested that for the majority of samples the phenotype of the leukemia cells differed before and after passage in NOD/SCID mice, 16 samples were subjected to a more detailed analysis using three-color
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Figure 5
Distribution of the engraftment of AML in NOD/SCID over the cytogenetic risk groups. Patients were stratified into cytogenetic risk groups according to the criteria as described in the Materials and methods section. Dark shaded bars: primary AML; light shaded bars: secondary AML. For further legends see Figure 1 .
Figure 6
Correlation between the level of chimerism observed in the bone marrow of NOD/SCID infused with primary AML samples and the white blood cell count observed in the respective patients at diagnosis. Each data point represents a single patient sample. Drawn lines indicate the fitted linear regression line and the calculated 95% confidence limits.
flow cytometry for the expression of CD33, CD34 and CD38 (Table 2 ). This analysis revealed that in 10 out of 16 samples the phenotype of the major populations changed with in vivo passage in the mice. The most frequent changes observed were a loss of CD34 expression accompanied by an increased expression of CD33 and CD38 (if those markers were not already expressed in the input population). Only in the FAB M0 class did we find changes in phenotype from CD33 Sixteen of a total of 27 patients were subjected to flow cytometric analysis of the co-expression of CD33, CD34 and CD38 before and after passage in NOD/SCID mice. The phenotypes given in this table are the phenotypes of the majority (representing more the 25% of all human cells) populations present in the samples. Samples marked as 'mix' had two major, phenotypically different, populations present. The size of these populations is given as the percentage of the total total AML population. a Samples which differed in the phenotypes of the populations present before and after passage in NOD/SCID.
The extent of autonomous or cytokine-induced in vitro proliferation does not correlate with NOD/SCID repopulation
There have been contrasting reports on the use of exogenous growth factors such as PIXY to enhance the level of engraftment in the AML-NOD/SCID model. To test if in vitro growth factor responsiveness or growth factor independence might be indicative for NOD/SCID repopulating ability of AML we studied the cytokine responsiveness using a tritiated thymidine assay (Table 3 ). All growth factor response data were corrected for the autonomous responses, ie the 3 H-TdR uptake in the absence of growth factors. Although large differences in response could be observed, especially with G-CSF and SCF, neither the growth factor-induced, nor the autonomous proliferation, proved to be indicative for repopulation of the NOD/SCID bone marrow. The secondary AML samples generally had both a higher autonomous proliferation and a higher cytokine-induced proliferation. However, differences between primary and secondary AML were found to be not significant at a level of P Ͻ 0.05 (data not shown).
NOD/SCID repopulation does not link with a specific leukemic cobblestone area-forming cell subset
The finding that in vitro incubation of AML with 5-FU depletes early week-type L-CAFC combined with the finding that these samples at least partially retain their NOD/SCID repopulating ability 5 led us to investigate whether we could find a correlation between the level of engraftment and L-CAFC frequencies. As shown in Figure 7 , no significant differences 895 Table 3 The responses of primary and secondary AML to growth factor stimulation and absence of correlation with in vivo NOD/SCID repopulation H-thymidine incorporation between the test sample and an irradiated control sample. All cytokine stimulation data were corrected for the component caused by the autonomous proliferation, thus explaining negative values.
Figure 7
Median frequencies of various leukemic-CAFC weektypes. Primary AML: dotted lines; secondary AML: solid lines.
were observed between the frequencies of L-CAFC week 1-2 in primary vs secondary AML. Frequencies of L-CAFC week 4-6 in secondary AML were at the lower threshold of detection, ie 1 per 10 6 cells and appeared to be reduced in comparison to the primary AML. No correlations could be observed between the level of engraftment and any of the L-CAFC week-types (Table 4) , nor could we find a correlation between L-CAFC frequencies and FAB type, cytogenetics or white blood cell counts in patients (data not shown). This table shows the correlation coefficients and the P values for Spearmans rho test when analyzing for a possible correlation between the L-CAFC frequencies for the given week-types and the level of human chimerism in the bone marrow of the NOD/SCID mice.
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Discussion
The availability of an in vivo assay for human AML progenitors responsible for the maintenance of the malignant clone(s) is important both for our understanding of the basic biology of AML as well as for the development of new therapeutic strategies.
Over the last few years, we and other groups have shown the ability of AML cells to engraft in NOD/SCID mice. However, one of the basic shortcomings of this model has been the low and unpredictable level of engraftment in this assay.
To our knowledge, this paper is the first to show that primary and secondary AML differ greatly in the ability to engraft NOD/SCID mice. In addition, we show that at least in primary AML repopulating capacity was highly correlated to the patient's white blood cell counts at diagnosis. Covariant analysis of the level of engraftment and FAB class with the patient's WBC as a covariant could not fully explain our results thus suggesting there is also a FAB-specific factor involved in determining the level of engraftment. Similar covariant analysis, with WBC counts as a covariant could, however, fully explain the correlation observed between the level of engraftment and the cytogenetic risk groups, ie poor, intermediate or good prognosis cytogenetics. The above findings might also explain a similar correlation with cytogenetics observed by Ailles et al, 26 who did not distinguish between primary and secondary AML, or looked at the relation with WBC. It might also explain why these authors observed different levels of engraftment in the various FAB classes.
For primary AML we were unable to find a correlation between the NOD/SCID repopulating ability and any of the L-CAFC week-type frequencies. We also could not find a cor-relation between L-CAFC week-types and any of the CD34/CD38 subpopulations, or between the CD34/CD38 subpopulations and repopulating ability. The latter two observations could be explained by assuming that both the SL-IC and L-CAFC only represent a minor subpopulation within any of the phenotypes. The absence of a correlation between NOD/SCID repopulating ability and any of the L-CAFC weektypes could imply that the SL-IC is either a subpopulation contained in any of the L-CAFC week-types, or is a cell more primitive than the L-CAFC week 6 and thus not detectable in our assay. However, taken together our observations suggest that: (1) there is a lack of correlation between L-CAFC frequencies and engraftment in the mice and (2) there is a high correlation between WBC counts and NOD/SCID repopulation. This strongly suggests that the level of engraftment reached might reflect the proliferative capacity of the AML cells rather than the number of SL-IC infused. However, this proliferative capacity could not be correlated with either the autonomous or cytokine-induced proliferation in short-term thymidine incorporation studies. If the proliferative capacity of the samples is one of the main variables determining the engraftment of NOD/SCID mice this would also imply that assessing the number of SL-IC by limiting dilution in NOD/SCID can be biased by the proliferative ability of the sample under investigation.
Although it has been observed that AML cells injected into NOD/SCID have a similar dissemination pattern as in patients, 16 we demonstrate here that in 10 of the 16 investigated samples the phenotype of the cells after passage in the mice differed markedly from the input phenotype. This phenotypic change of the infused cells may have been due to the fact that a subclone with the phenotype observed after passage is responsible for outgrowth, or that the AML cells undergo a different differentiation pattern in mice than in patients.
Whilst from our previous study 27 it has become clear that the presence of internal tandem duplications in the Flt3 gene in AML favors the outgrowth of these samples in the NOD/SCID model, the current study has been able to identify some additional important variables involved in determining the NOD/SCID repopulating ability of the Flt3 gene wildtype population.
Our present identification of parameters that determine the outgrowth of AML samples in NOD/SCID mice may contribute in selecting patient samples for therapy development in these immunodeficient mice.
